Search results
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
The Wall Street Journal· 6 days agoHEALTH NEWS Bristol Myers Squibb said on Friday that its trial evaluating a combination of cancer...
Bristol Myers Squibb reports setback in lung cancer trial By Investing.com
Investing.com· 6 days agoBristol Myers Squibb (NYSE: NYSE:BMY) disclosed that its Phase 3 CheckMate -73L trial for treating a...
CORRECTED-UPDATE 3-US FDA approves expanded use of Bristol Myers' cancer cell therapy (May 15)
Reuters via Yahoo Finance· 19 hours agoThe U.S. health regulator on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi for the treatment of adults with a type of blood cancer called follicular ...
US FDA approves expanded use of Bristol Myers' cancer cell therapy
Reuters· 19 hours ago, opens new tab cancer cell therapy Breyanzi for the treatment of adults with a type of blood cancer...
Big Pharma layoffs continue, as Bristol-Myers Squibb cuts 2,200 jobs, $1.5B in costs
BenefitsPRO· 6 days agoAt a time when drugmakers Eli Lilly & Co. and Novo Nordisk are scrambling to meet demand for their...
US FDA approves expanded use of Bristol's cancer cell therapy
Reuters via Yahoo Finance· 19 hours agoMay 15 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to include the treatment of adults with ...
News Highlights: Top Company News of the Day - Friday at 7 PM ET
Morningstar· 6 days agoBristol Myers Squibb said its trial evaluating a combination of cancer treatments failed to meet its primary endpoint. The television company, which produces "The Walking Dead," cited "declines ...
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
InvestorPlace· 5 hours agoIt’s no secret that artificial intelligence (AI) promises to transform every industry and sector,...
One stock is dragging down the S&P 500's earnings growth
AOL· 3 days agoCompanies in the S&P 500 (^GSPC) have reported what's broadly been considered a solid Q1 earnings season for the index, with one key exception: drugmaker Bristol Myers Squibb (BMY). Last month ...
US FDA approves expanded use of Bristol Myers' cancer cell therapy (May 15)
AOL· 19 hours agoThe Food and Drug Administration's decision marks the fourth approval for Breyanzi, which can now be used to treat follicular lymphoma patients who have received two or more prior lines of therapy ...